Head to head
Medline vs Intuitive Surgical
Side-by-side on the measures that matter, with a plain-English read. Full detail: MDLN · ISRG
MDLN
Medline
37.04-2.11%
1-year price shape — not enough history yet
Quant Rating D · 0/100
vs
ISRG
Intuitive Surgical
399.05-2.01%
1-year price shape — -28% over the period
Quant Rating E · 15/100
1-year performance, rebased to 100
Intuitive Surgical edges it on the scoreable measures. Intuitive Surgical has the highest Quant Rating (15); Intuitive Surgical trades cheapest on trailing earnings; Intuitive Surgical earns the most per share.
| MDLN | ISRG | |
|---|---|---|
| Snapshot | ||
| Sector | -- | -- |
| Last price | 37.04 | 399.05 |
| Change today | -2.11% | -2.01% |
| 1-year return | -- | -27.7% |
| Market cap | $32.55B | $138.33B |
| 52-week range | 31.37 – 50.88 | 328.57 – 603.88 |
| Valuation | ||
| P/E (TTM) | 57.52 | 48.25 |
| P/E percentile, own 5-yr range | 69th | 16th |
| P/B | 2.76 | 8.65 |
| Dividend yield | 0.00% | 0.00% |
| Profitability & growth | ||
| EPS (TTM) | 1.43 | 7.87 |
| Net profit (TTM) | $1.25B | $2.73B |
| Revenue (TTM) | $30.68B | $11.58B |
| Provider revenue period date | 2026-09-25 | 2026-09-29 |
| Revenue growth (YoY) | +10.4% | +21.7% |
| Gross margin | 25.7% | 67.2% |
| Operating margin | 5.7% | 32.3% |
| Net margin | 1.8% | 25.5% |
| Free cash flow (TTM) | $1.90B | $3.60B |
| Provider cash-flow period date | 2026-09-25 | 2026-09-29 |
| Ownership & sentiment | ||
| Institutional ownership | 119.9% | 86.7% |
| Insider activity (12mo) | 20 buy / 30 sell | 17 buy / 33 sell |
| Short interest (% of float) | 4.3% | 2.0% |
| Analyst consensus | 100% buy (17) | 100% buy (18) |
| Analyst price target | $48 (+29%) | $516 (+29%) |
| StockVane view | ||
| StockVane Quant Rating | D (0) | E (15) |
| Company | ||
| Employees | 45,000 | 17,021 |
| Founded | 1966 | 1995 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.